This is in accordance with clinical observations in which CML patients may relapse even after prolonged TKI therapy when BCR::ABL1 has been undetectable for a longer time [22]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.